Lenacapavir is a twice-yearly injection that can prevent HIV infections. New licensing deals with Gilead and Indian manufacturers mean it will be available in 120 low- and middle-income countries at about US$40 a year.
The Gates Foundation will help Hetero with funding and volume guarantees and says it invested more than US$80 million to speed production. Dr. Reddy’s will receive help from the Clinton Health Access Initiative, Unitaid and Wits RHI to supply generics from 2027 at the same price. Campaigners warn some middle-income countries are excluded and that money is also needed for awareness, training and supply.
Difficult words
- drug — A substance used for medical treatment.
- injection — A shot given using a needle.
- countries — Nations or areas with their own governments.
- access — The ability to use or reach something.
- funding — Money provided for a specific purpose.
- healthcare — Services related to health and medical care.
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Why is lenacapavir considered a major step in fighting HIV?
- How do you think funding can improve healthcare services?
- What might happen if middle-income countries are excluded from access?
Related articles
Gene and blood‑vessel damage add to dementia risk
Researchers studied a genetic variant (APOE ε4) and white matter hyperintensities (WMH), a sign of small blood‑vessel damage. They found both factors raise dementia risk additively, and vascular health may be improved to lower that risk.
Mpox may be spreading quietly in Nigeria
A study in Nigeria tested archived blood from healthy adults and found signs of hidden mpox exposure. Some people had old smallpox antibodies and a small number showed recent immune responses without symptoms, suggesting low-level virus circulation.
Lower mGlu5 receptor found across autistic adult brains
A study in The American Journal of Psychiatry found lower availability of a glutamate receptor called mGlu5 across the brains of autistic adults. Researchers used PET, MRI and EEG and say the result could affect future diagnosis and treatment.